DNAPrint to Present RETINOME Launch and Other Advancements at Upcoming Conferences
SARASOTA, Fla.--(BUSINESS WIRE)--April 30, 2002--DNAPrint genomics, Inc.'s (OTCBB:DNAP) innovation within the field of complex genomics has landed the company two more prestigious speaking engagements.
DNAPrint has accepted an invitation to present at the upcoming Cambridge Healthtech Institute's (CHI) Fifth Annual "DNA Forensics" symposium to be held June 24-28, 2002 in Washington D.C., and at the National Managed Health Care Congress (NMHCC) "Disease Management Congress" to be held September 16-20 in Chicago, IL.
At CHI's DNA Forensics meeting, DNAPrint plans to announce the beta launch of the company's RETINOME(TM) V1.0 genetic eye color test to the forensics science community. In addition, Dr. Tony Frudakis, CEO, will discuss company progress developing and commercializing other complex genetics classifiers of forensics value. Comprised of officials and scientists from the Federal Bureau of Investigation, Department of Defense, National Institute of Standards and Technology, numerous state forensics laboratories, and many of the world's leading companies that develop products for forensics sciences (Orchid - "ORCH", Applera - "ABI", Myriad Genetics - "MYGN", Third-Wave - "TWTI" etc.), the audience represents a healthy cross-section of the RETINOME(TM) target market.
At NMHCC's Disease Management Congress, DNAPrint intends to convince an audience of Managed Health Care administrators, government officials, hospital administrators, physicians and clinical scientists that pharmacogenomics classifiers, in the company's view, are the cornerstone of the most important near-term benefits humanity will realize from the recently completed human genome project. Dr. Frudakis will discuss company progress solving various drug reaction traits that have, because of their complex nature, vexed scientists and physicians to date. In addition, he will outline why and how genomics advances and innovative mathematics have enabled progress towards an individualization of drug prescription.
About RETINOME(TM):
RETINOME(TM) is the world's first and only complex genomics classifier for the inference of human iris color from DNA, capable of iris color inference with greater than 99% accuracy and iris color shade with significantly greater than 99% accuracy. The company hopes the product will enhance and facilitate criminal investigations based on DNA evidence by complementing standard (STR) DNA tests. At present, STR tests are the only player in the current billion dollar identity testing market world-wide, but they are only useful for ascribing genetic bar-codes to individuals. Unlike STR tests, RETINOME(TM) is capable of revealing qualitative information (iris colors) that can be used to describe the physical characteristics of an anonymous DNA donor. DNAPrint announced the break-through(s) that led to the development of RETINOME(TM) last October at TIGR's Genome Sequence and Analysis (GSAC) conference and has since presented the product on ABC news, in International and US newspapers, and at bioinformatics/genomics conferences. DNAPrint intends to commercialize the test to the US forensics community by year's end, and to other forensics scientists throughout the world by the end of 2003.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
Carrie Castillo, 941/366-3400 |
